Pancreatic Cancer Research

ResearcherVA Greater Los Angeles Healthcare SystemActive in the last 2 years

Greg D. Sacks

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-1205-6477; OpenAlex author ID A5006975582. Sources: ClinicalTrials.gov.

Their work

Papers
28 (first author 2, last author 6)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
79
Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: 1 paper, 1 trial · 2024: 5 papers · 2025: 16 papers · 2026: 5 papers

Papers 28

  1. Clinical and molecular features of resected early onset pancreatic ductal adenocarcinoma: insights from the NCDB and cBioPortal. Co-author DOI 10.1016/j.hpb.2025.12.026↗
  2. Does ductal subtype predict outcomes after resection of IPMN-derived pancreatic cancer? An international multi-center retrospective study. Last author DOI 10.1016/j.hpb.2026.08.011↗
  3. Postpancreatectomy liver injury: A relevant entity in the modern era of pancreatic cancer surgery with hepatic vessel resection. A monocentric retrospective co… Co-author DOI 10.1016/j.surg.2026.110302↗
  4. Informing Decision-making for Transected Margin Reresection in Intraductal Papillary Mucinous Neoplasm-derived Pancreatic Cancer: An International Multicenter … Co-author DOI 10.1097/sla.0000000000006532↗
  5. Proposal for an Objective and Concrete Definition for Determining Anatomic Resectability in Pancreatic Cancer: The Concept of the "Suitable Target". Co-author DOI 10.1097/xcs.0000000000001738↗
  6. Longitudinal assessment of disparities in pancreatic cancer care: A retrospective analysis of the National Cancer Database. Co-author DOI 10.1002/wjs.12431↗
  7. Risk of pancreatic cancer and high-grade dysplasia in resected main-duct and mixed-type intraductal papillary mucinous neoplasms: A prevalence meta-analysis. Last author DOI 10.1016/j.ejso.2025.109742↗
  8. Reply to: Comment on "Risk of pancreatic cancer and high-grade dysplasia in resected main-duct and mixed-type intraductal papillary mucinous neoplasms: A preva… Last author DOI 10.1016/j.ejso.2025.110111↗
  9. Moving Beyond the Standard Pancreatectomy for Pancreatic Adenocarcinoma. Co-author DOI 10.1016/j.semradonc.2025.08.001↗
  10. Impact of resection margin status on recurrence and survival in patients with resectable, borderline resectable, and locally advanced pancreatic cancer. Co-author DOI 10.1016/j.surg.2024.109114↗
  11. Recognizing IPMN-derived pancreatic cancer as a specific entity requiring prospective clinical studies: a call for international collaboration. Co-author DOI 10.1093/jnci/djaf037↗
  12. Time-varying impact of established prognostic factors in resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/jnci/djaf196↗
  13. Neoadjuvant Chemotherapy for Intraductal Papillary Mucinous Neoplasm-derived Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006687↗
  14. Carbohydrate Antigen 19-9 Delta Function for Survival Prediction in Borderline Pancreatic Cancer. A PANC-PALS Consortium International Multicenter Derivation a… Co-author DOI 10.1097/sla.0000000000006735↗
  15. Transitional Type Circulating Tumor Cells Predict Systemic Recurrence and Support Risk Stratification for Chemotherapy After Resection of Pancreatic Ductal Ade… Co-author DOI 10.1097/sla.0000000000006998↗
  16. Defining and Predicting Early Recurrence for Optimal Treatment Strategies for Intraductal Papillary Mucinous Neoplasm-Derived Pancreatic Cancer: An Internation… Co-author DOI 10.1245/s10434-024-16649-z↗
  17. Two-Stage Mayo Clinic Class IIIb Celiac Axis Resection for Pancreatic Adenocarcinoma: Stepwise Management. Co-author DOI 10.1245/s10434-024-16673-z↗
  18. Incidence and Outcomes of Intraductal Oncocytic Papillary Neoplasm-Derived Pancreatic Cancer Compared with Tubular and Colloid Intraductal Papillary Mucinous N… Last author DOI 10.1245/s10434-025-17810-y↗
  19. ASO Author Reflections: Old Truths, New Data: Intraductal Oncocytic Papillary Neoplasm-Derived Pancreatic Cancer Requires Continued Surveillance. Last author DOI 10.1245/s10434-025-18007-z↗
  20. The Impact of Social Determinants on Pancreatic Cancer Care in the United States. Last author DOI 10.3390/cancers17121898↗
  21. The Impact of Social Determinants of Health on Supportive and Palliative Care in Pancreatic Cancer Management: A Narrative Review. Co-author DOI 10.3390/cancers17193254↗
  22. The impact of metastatic sites on survival Rates and predictors of extended survival in patients with metastatic pancreatic cancer. Co-author DOI 10.1016/j.pan.2024.06.004↗
  23. An international multi-institutional validation of T1 sub-staging of intraductal papillary mucinous neoplasm-derived pancreatic cancer. Co-author DOI 10.1093/jnci/djae166↗
  24. Progression of Site-specific Recurrence of Pancreatic Cancer and Implications for Treatment. Co-author DOI 10.1097/sla.0000000000006142↗
  25. Outcomes in intraductal papillary mucinous neoplasm-derived pancreatic cancer differ from PanIN-derived pancreatic cancer. Co-author DOI 10.1111/jgh.16686↗
  26. Development of a Composite Score Based on Carbohydrate Antigen 19-9 Dynamics to Predict Survival in Carbohydrate Antigen 19-9-Producing Patients With Pancreati… Co-author DOI 10.1200/po.24.00193↗
  27. Natural History of Stage IV Pancreatic Cancer. Identifying Survival Benchmarks for Curative-intent Resection in Patients With Synchronous Liver-only Metastases. First author DOI 10.1097/sla.0000000000005753↗
  28. Long-term survival in patients with pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.surg.2015.12.024↗

Trials 1

  1. Clinician Decision Making Regarding Surveillance for Low-risk Intraductal Papillary Mucinous Neoplasms of The Pancreas Principal investigator NCT06311032↗

Closest collaborators

The 25 strongest of 79 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ammar A. Javed · 24 shared papers, 2024–2026 · strength 5.41
  2. Daniel Brock Hewitt · 18 shared papers, 2024–2026 · strength 3.83
  3. Joseph R. Habib · 18 shared papers, 2024–2026 · strength 3.82
  4. Christopher Lee Wolfgang · 15 shared papers, 2024–2026 · strength 3.33
  5. Ingmar Florin Rompen · 15 shared papers, 2024–2026 · strength 3.07
  6. Camila Hidalgo Salinas · 9 shared papers, 2025–2026 · strength 2.11
  7. Christopher L. Wolfgang · 9 shared papers, 2024–2025 · strength 1.96
  8. Lois A. Daamen · 9 shared papers, 2024–2026 · strength 1.79
  9. Izaak Quintus Molenaar · 9 shared papers, 2024–2026 · strength 1.79
  10. Marc G. Besselink · 9 shared papers, 2024–2026 · strength 1.79
  11. Paul C. M. Andel · 9 shared papers, 2024–2026 · strength 1.73
  12. Alessio Marchetti · 7 shared papers, 2025–2026 · strength 1.57
  13. Brian J. Kaplan · 7 shared papers, 2024–2026 · strength 1.57
  14. Michael D. Kluger · 6 shared papers, 2025–2026 · strength 1.55
  15. Brady A. Campbell · 8 shared papers, 2024–2026 · strength 1.55
  16. Jonathan Garnier · 5 shared papers, 2024–2026 · strength 1.11
  17. Omar Mahmud · 4 shared papers, 2025–2026 · strength 1.06
  18. Mahip Grewal · 4 shared papers, 2024–2025 · strength 0.99
  19. Martin Loos · 5 shared papers, 2024–2026 · strength 0.95
  20. Benedict Kinny‐Köster · 5 shared papers, 2024–2026 · strength 0.95
  21. Kelly J. Lafaro · 5 shared papers, 2024–2025 · strength 0.89
  22. Jonah M. Levine · 4 shared papers, 2024–2026 · strength 0.83
  23. Adrian Theophil Billeter · 4 shared papers, 2025–2026 · strength 0.80
  24. Markus Wolfgang Büchler · 4 shared papers, 2024–2026 · strength 0.78
  25. Jing He · 4 shared papers, 2024–2026 · strength 0.76

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.